The practitioner placed a small glass vial in my open palm and closed my fingers around it.
“Resist,” she said, pressing down on my extended arm.
My arm dropped like she’d hung a weight from it.
She set the vial aside, wrote something on a chart, and reached for the next one. We repeated the test thirty times. I was in my late twenties, newly a cat owner, and so allergic I couldn’t breathe through my nose for months. I’d tried all the traditional treatments and nothing held. A colleague mentioned acupuncture. I didn’t believe in it. I went anyway, because I was out of options.
The vial test was supposed to identify my sensitivities through some principle of energetic resonance I couldn’t parse. The theory was that my body would weaken in the presence of whatever was causing the reaction. The practitioner mapped the results onto an energy chart I couldn’t read, placed needles I couldn’t feel along meridians I couldn’t see, and sent me home with instructions I couldn’t explain to anyone.
The allergies went away.
I wasn’t a trained scientist then, though I was always innately one. I understood that my improvement proved nothing about the efficacy of acupuncture or homeopathy. Placebo is real. Allergies resolve on their own. Regression to the mean is the most underrated force in medicine. One uncontrolled recovery establishes nothing.
But I got better. And I’d go back.
The question that stayed with me was not whether the institution was right about acupuncture. The question was simpler and harder: who gets to decide what the best available treatment is for me?
The Richest Homeopathist in America
The richest man in America held exactly the same position.
John D. Rockefeller relied on a homeopath for decades. His personal physician, Hamilton Fisk Biggar, practiced homeopathy, a medical tradition that treated illness with highly diluted preparations rather than the drugs and surgery that mainstream medicine was adopting. In 1916, Rockefeller told his staff plainly: “I am a homeopathist.” The Rockefeller Institute hospital reserved rooms for the family. Rockefeller himself never used them. He kept seeing his homeopath.
While Rockefeller privately chose the medicine his own experience validated, his philanthropic apparatus was reshaping the competitive environment in which medical legitimacy was produced.
His chief philanthropic adviser, Frederick T. Gates, approached philanthropy systemically. His governing logic for the General Education Board was captured in a single word. “The key word,” he wrote, “was the word system.”
In 1910, Abraham Flexner published his report evaluating every medical school in America against the Johns Hopkins standard. Flexner was not a physician. He was an educator whose brother directed the Rockefeller Institute. The report was funded by Dale Carnegie. Beginning in 1913, the General Education Board directed tens of millions of dollars into a selected group of medical schools, with conditions: full-time faculty, university control, laboratories, hospital affiliation. Schools that met the standard thrived. Schools that didn’t vanished.
Before 1900, American medicine included roughly twenty-two homeopathic medical schools. By 1923, two remained. By 1950, none. Homeopathy’s decline involved internal fragmentation and the genuine advances of conventional medicine alongside the institutional transformation that Rockefeller’s capital helped accelerate. What emerged was a single institutional standard for producing and validating medical knowledge, enforced not through prohibition but through the economics of who could meet the standard and who could not.
The Monopoly on Success
The system produced extraordinary advances. Laboratory medicine. Pharmacology. Clinical training. Surgical technique. Research methodology that became the global standard for evaluating whether a treatment works. Scientific medicine deserved much of the authority it accumulated.
The problem is not that the system failed. The problem is that its success came bundled with a monopoly on deciding what counted as success.
If you are the person whose allergies resolved through a treatment the institution dismisses, you are not anti-science. You are underserved by a system that demands evidence for legitimacy while directing the money, infrastructure, and scientific attention that determine which questions ever get the chance to produce it. The supply of scientific attention is finite, and it flows where institutional incentives direct it. Some questions never receive institutional attention at all.
But bodily sovereignty presents a harder problem than neglected questions.
The institution may have investigated your condition thoroughly. It may have produced rigorous, well-powered, preregistered trials. The evidence may be excellent by every standard the institution recognizes. And it may still not answer the question you are actually asking, which is whether this particular treatment will work for you, given your body, your history, your baseline.
Evidence about populations and decisions about one person are not identical epistemic objects. A treatment can have one credible average relative effect in a trial and still offer very different absolute value to different patients, because patients enter trials at vastly different baseline risk. The population average describes what happens across a group. It cannot tell you what will happen to you. The person whose body sits at the edge of that distribution is not an error in the data. They are a person the population average cannot completely describe.
The Experiment of One
AI-empowered citizen science gives that individual something that was rarely within reach: the ability to apply scientific rigor independently to questions the institution will not ask and to questions whose population-level answers do not resolve the individual case.
A properly designed N-of-1 experiment is not guesswork. It is a structured protocol with randomization, blinding where feasible, and longitudinal measurement that generates causal evidence tailored to one person. When the methodology was formalized in the 1980s, the operational barriers were prohibitive. Repeated-crossover designs could require pharmacy support, careful measurement, statistical expertise, and substantial clinical coordination, putting rigorous N-of-1 experimentation beyond the practical reach of most patients acting independently.
Those barriers are dissolving. Continuous glucose monitors, direct-to-consumer laboratories, wearables, and community biolabs have made capabilities formerly bundled inside institutions separately accessible. The person who twenty years ago had little ability to rigorously test a population-level conclusion for themselves can now design an experiment calibrated to their own physiology and their own question. AI lowers the remaining expertise threshold, but the causal credibility still comes from the experimental design, not the model.
AI works like a centrifuge in these moments. It doesn’t judge which response is better. It separates them. One person reads that the institution dismissed a treatment and repeats the dismissal without examining it. Another reads the same thing and designs the experiment that would change the answer for their specific case. The difference is not compliance versus defiance. It is consumption of consensus versus investigation of it.
The Regulatory Landscape
The regulatory landscape reflects this distinction more than most people realize. Regulatory burdens become substantially heavier when activity involves manufacturing for others, distribution, commercial claims, formal clinical investigation, or deployment at population scale. Many private health decisions operate under different legal conditions. Off-label prescribing exists within medical practice. The Common Rule governs research designed to produce generalizable knowledge, not every personal health activity. Pathways like Expanded Access and Right to Try, though narrow and condition-specific, demonstrate that even regulatory structures acknowledge individualized access to investigational treatments.
The Technology for Manufacturing Legitimacy
The institution is not legitimacy itself. It has been a technology for manufacturing legitimacy at scale, because there was historically no cheaper way to produce it.
Therapeutic performance compounded the authority. And for a century, that arrangement held because no alternative could match its combination of rigor, reach, and trust.
The components of that arrangement are separating. Provenance, verification, longitudinal measurement, safety surveillance, quality assurance. These are becoming distributed services rather than functions that must be bundled inside institutions. Not overnight. Not without new infrastructure, new trust mechanisms, and new mistakes along the way.
The richest man in America quietly exempted himself from the system’s conclusions every time he visited Hamilton Fisk Biggar’s office instead of the hospital that bore his own name.
The next system doesn’t have to make the same trade. The question is whether we will build the trust infrastructure that lets everyone else make the choice Rockefeller kept for himself.